129 related articles for article (PubMed ID: 36681255)
1. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K
Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
4. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
6. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
[TBL] [Abstract][Full Text] [Related]
7. Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.
Yohannes AM; Iyer AS; Clay C; Cochran L; Chen X; Lombardi DA; Bhatt SP
Chronic Obstr Pulm Dis; 2024 Mar; 11(2):196-205. PubMed ID: 38241514
[TBL] [Abstract][Full Text] [Related]
8. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD.
Donohue JF; Mahler DA; Sethi S
Int J Chron Obstruct Pulmon Dis; 2019; 14():2947-2958. PubMed ID: 31908443
[TBL] [Abstract][Full Text] [Related]
9. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
10. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
[TBL] [Abstract][Full Text] [Related]
12. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Li F; Yang J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
[TBL] [Abstract][Full Text] [Related]
13. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
[TBL] [Abstract][Full Text] [Related]
15. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
[TBL] [Abstract][Full Text] [Related]
16. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
17. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
18. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
[TBL] [Abstract][Full Text] [Related]
20. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
